Benjamin F. Edwards & Company Inc. Acquires 4,207 Shares of Sanofi (NASDAQ:SNY)

Benjamin F. Edwards & Company Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY) by 33.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 16,737 shares of the company’s stock after acquiring an additional 4,207 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Sanofi were worth $812,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Congress Wealth Management LLC DE purchased a new stake in shares of Sanofi during the fourth quarter valued at $226,000. Johnson Financial Group Inc. bought a new position in Sanofi in the 4th quarter worth about $31,000. Catalytic Wealth RIA LLC bought a new position in Sanofi in the 4th quarter worth about $346,000. Manhattan West Asset Management LLC increased its position in shares of Sanofi by 57.6% during the fourth quarter. Manhattan West Asset Management LLC now owns 67,928 shares of the company’s stock worth $3,378,000 after acquiring an additional 24,817 shares during the period. Finally, Scotia Capital Inc. raised its stake in shares of Sanofi by 186.8% during the fourth quarter. Scotia Capital Inc. now owns 13,411 shares of the company’s stock valued at $667,000 after acquiring an additional 8,735 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

Shares of SNY stock opened at $57.43 on Tuesday. The stock’s 50-day moving average is $54.34 and its 200 day moving average is $50.52. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market cap of $145.45 billion, a P/E ratio of 28.86, a PEG ratio of 1.62 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.95 earnings per share. Research analysts predict that Sanofi will post 4.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SNY shares. Argus lifted their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Friday. Three analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.